HDTRA118C0001

DEVELOP NOVEL AND INNOVATIVE SMALL MOLECULE THERAPEUTICS TO TREAT (POST-EXPOSURE THERAPEUTIC) INFECTIONS BY BOTH FILOVIRUS FAMILY MEMBERS (EBOLA VIRUSES AND MARBURG VIRUSES)

Defense Contract Management Agency · United States

This tender closed on Friday, December 14, 2018. Browse open opportunities

View Source

Time Left to Bid

Closed

ClosedDefence & SecurityFederal

Basic information

Reference number: HDTRA118C0001
Issuing organization: Defense Contract Management Agency · Find award history →
Government level: Federal
Solicitation type: Defence & Security
Title: DEVELOP NOVEL AND INNOVATIVE SMALL MOLECULE THERAPEUTICS TO TREAT (POST-EXPOSURE THERAPEUTIC) INFECTIONS BY BOTH FILOVIRUS FAMILY MEMBERS (EBOLA VIRUSES AND MARBURG VIRUSES)
Source: USASpending (Federal)
Source ID: usa-HDTRA118C0001

Details

Location: United States

Description

DEVELOP NOVEL AND INNOVATIVE SMALL MOLECULE THERAPEUTICS TO TREAT (POST-EXPOSURE THERAPEUTIC) INFECTIONS BY BOTH FILOVIRUS FAMILY MEMBERS (EBOLA VIRUSES AND MARBURG VIRUSES) Awarded to: MICROBIOTIX, INC. Agency: Department of Defense Sub-agency: Defense Contract Management Agency Award type: DEFINITIVE CONTRACT

Dates

Publication: 2017/12/15 12:00:00 AM UTC
Closing date: 2018/12/14 12:00:00 AM UTC

Estimated value

$2.6M USD

Classification

Normalized category

Defence & Security

Source: USASpending (Federal)

Last updated 2026-05-25, 2:08:35 p.m.

Data refreshed every 2 hours